All Eyes On Antitrust Enforcement In China’s Pharmaceutical Industry

By Adrian Emch & Jiaming Zhang –
August 1, 2016 marks the eighth anniversary of the entry into effect of China’s Anti-Monopoly Law (“AML”). Enforcement of the law has gone through various phases, with the peak – at least in terms of press coverage – during 2014, culminating in the Qualcomm decision by the National Development and Reform Commission in February 2015.
Since the 2015 Qualcomm decision, Chinese antitrust enforcement has been less headline-grabbing and, generally s...